Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000819526 | SCV000960191 | uncertain significance | Familial cancer of breast | 2018-09-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The proline amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CHEK2-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with proline at codon 104 of the CHEK2 protein (p.Ala104Pro). The alanine residue is weakly conserved and there is a small physicochemical difference between alanine and proline. |
| Baylor Genetics | RCV000819526 | SCV004217546 | uncertain significance | Familial cancer of breast | 2023-09-20 | criteria provided, single submitter | clinical testing |